Neumora Therapeutics (NMRA) Retained Earnings (2022 - 2026)

Neumora Therapeutics' Retained Earnings history runs 5 years deep, the most recent figure standing at -$1.2 billion for Q1 2026.

• On a quarterly basis, Retained Earnings fell 21.91% year-over-year to -$1.2 billion in Q1 2026; TTM through Mar 2026 was -$1.2 billion, a 21.91% decrease from a year earlier, with the FY2025 full-year figure at -$1.2 billion, down 25.01% from the prior year.
• Retained Earnings eased to -$1.2 billion in Q1 2026 per NMRA's latest filing, from -$1.2 billion in the prior quarter.
• Across five years, Retained Earnings topped out at -$15000.0 in Q2 2025 and bottomed at -$1.2 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$444.6 million (2022), against an average of -$533.2 million.
• Across the five-year window, Retained Earnings plunged 1246243.42% in 2024 and jumped 91.98% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$774000.0 in 2022, then soared by 90.18% to -$76000.0 in 2023, then plunged by 1246243.42% to -$947.2 million in 2024, then dropped by 25.01% to -$1.2 billion in 2025, then declined by 4.51% to -$1.2 billion in 2026.
• Per Business Quant, the three latest NMRA Retained Earnings figures stand at -$1.2 billion (Q1 2026), -$1.2 billion (Q4 2025), and -$1.1 billion (Q3 2025).